Absence of effects of long-term growth hormone replacement therapy on insulin sensitivity in adults with growth hormone deficiency of childhood-onset (GHDA-CO).
In order to assess long-term efficacy and safety of GH therapy in GHDA-CO, we studied 20 patients (8 female, 12 male; mean age 24.6+/-6.2 years) treated with GH for up to 24 months. The assessment (IGF-1, IGFBP3, lipid profile, body composition, glycated hemoglobin, oral glucose tolerance test, ISI-HOMA and ISI-composite derived from OGTT) was carried out before GH and every 3 months during the first year of treatment, and then every 6 months. We observed a significant increase of IGF-1, lean mass and HDL levels and a decrease in LDL levels. Fasting glucose presented a significant increase, within the normal range, after 6 months, returning to pre-treatment levels at 9 months with no further alteration. Fasting insulin, the areas under the glucose and insulin curves, ISI-HOMA and ISI-composite did not vary significantly. We conclude that long-term GH therapy improved body composition and lipid profile, without altering ISI in this cohort of patients with GHDA-CO.
Knoepfelmacher
Mirta
M
Endocrine Unit, Hospital das Clínicas, University of São Paulo Medical School, 05403-900 São Paulo, Brazil. mirta@uol.com.br
Jallad
Raquel Soares
RS
Liberman
Bernardo
B
D000328:Adult; D017668:Age of Onset; D002648:Child; D005260:Female; D005947:Glucose / Q000032:analysis; D006130:Growth Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D019382:Human Growth Hormone / Q000009:adverse effects / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male
D007328:Insulin; D019382:Human Growth Hormone; D005947:Glucose